Journal: PLOS One
Article Title: 3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth
doi: 10.1371/journal.pone.0329706
Figure Lengend Snippet: (A) Viability of NSCLC cells (HCC827 and HCC827GR) treated for 24 (black) and 48 h (white) with Ru-B (2, 4, 6, and 8 µM), ARu-B (2, 4, and 6 µM), gefitinib (GEF, 1 µM), and savolitinib (SAV, 2 nM) as monitored by the MTT assay. Data are shown as the mean ± SD (n = 3). (B) Cell viability of HEKa cells treated as in (A). (C) and (D) The soft agar assay was used to determine anchorage-independent colony growth in NSCLC cells (14 days of incubation). (C) Micrograph of the cells on day 14 and (D) colony number. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to vehicle only. Scale bar, 400 µm.
Article Snippet: HCC827 (GEF-sensitive NSCLC cell line) and HEKa (Human epidermal keratinocytes) cells were purchased from the ATCC (American Type Culture Collection, Manassas, USA).
Techniques: MTT Assay, Soft Agar Assay, Incubation